Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
BALTIMORE-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced it will be featured as a presenting company at the 23rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on September 9, 2016, at the Millennium Broadway Hotel in New York City.
Dr. Uli Hacksell, President and Chief Executive Officer of Cerecor, will provide an overview of the Company’s business during a live presentation at 9:30 a.m. (Eastern Time) and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
About Cerecor
Cerecor is a clinical-stage
biopharmaceutical company developing innovative drug candidates to make
a difference in the lives of patients with neurological and psychiatric
disorders. We are committed to the development of drugs that improve
lives by applying our extensive knowledge and experience in central
nervous system disorders. Cerecor is currently pursuing the development
of two clinical Phase 2-stage product candidates: CERC-301 and CERC-501.
CERC-301 is an oral, NR2B specific N-methyl-D-aspartate (NMDA) receptor antagonist that is currently in a Phase 2 clinical trial as an oral, rapidly acting adjunctive treatment for patients with severe major depressive disorder (MDD) who are failing to achieve an adequate response to their current antidepressant treatment, with a rapid onset of effect. We expect top-line data from this trial in the first half of 2017. Cerecor received fast track designation by the United States Food and Drug Administration in November 2013 for CERC-301 for the treatment of MDD. We believe CERC-301 has the potential to be a first-in-class medication that may significantly reduce depressive symptoms in a matter of days.
CERC-501 is a potent and selective kappa opioid receptor (KOR) antagonist that is currently in a Phase 2 clinical trial for smoking cessation that is expected to provide top-line data in December 2016. In addition to Cerecor’s Phase 2 trial, three externally-funded clinical trials are being conducted to evaluate the use of CERC-501 in treating depressive symptoms, stress related smoking relapse and cocaine addiction. One study is being conducted under the auspices of the National Institute of Mental Health, the second is collaboration between Cerecor and Yale investigators with National Institutes of Health funding and the third study is being conducted at Rockefeller University Hospital and is funded by a private foundation.
Cerecor has one preclinical stage asset, CERC-406, a brain penetrant catechol-O-methyltransferase (COMT) inhibitor with potential procognitive activity.
For more information about the Company and its products, please visit www.cerecor.com or contact Mariam E. Morris, Chief Financial Officer, at (443) 304-8002.
Forward-Looking Statements
This press release may include
forward-looking statements made pursuant to the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are statements
that are not historical facts. Such forward-looking statements are
subject to significant risks and uncertainties that are subject to
change based on various factors (many of which are beyond Cerecor’s
control), which could cause actual results to differ from the
forward-looking statements. Such statements may include, without
limitation, statements with respect to Cerecor’s plans, objectives,
projections, expectations and intentions and other statements identified
by words such as “projects,” “may,” “will,” “could,” “would,” “should,”
“continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,”
“anticipates,” “estimates,” “intends,” “plans,” “potential” or similar
expressions (including their use in the negative), or by discussions of
future matters such as the development of product candidates or
products, technology enhancements, possible changes in legislation, and
other statements that are not historical. These statements are based
upon the current beliefs and expectations of Cerecor’s management but
are subject to significant risks and uncertainties, including those
detailed in Cerecor’s filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the
forward-looking statements. Except as required by applicable
law, Cerecor expressly disclaims any obligations or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Cerecor’s
expectations with respect thereto or any change in events, conditions or
circumstances on which any statement is based.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005200/en/
MacDougall Biomedical Communications
Doug MacDougall or Joe Rayne,
781-235-3060
ir@cerecor.com
Source: Cerecor Inc.
Released September 1, 2016